Published in Antimicrob Agents Chemother on December 01, 1993
Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother (1996) 2.13
Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor. J Virol (1995) 2.05
Antiviral therapy for human immunodeficiency virus infections. Clin Microbiol Rev (1995) 1.49
Protease inhibitors as antiviral agents. Clin Microbiol Rev (1998) 1.25
Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and protease. Antimicrob Agents Chemother (1995) 0.98
Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors. Antimicrob Agents Chemother (2002) 0.95
Potency and selectivity of inhibition of human immunodeficiency virus protease by a small nonpeptide cyclic urea, DMP 323. Antimicrob Agents Chemother (1994) 0.89
DMP 323, a nonpeptide cyclic urea inhibitor of human immunodeficiency virus (HIV) protease, specifically and persistently blocks intracellular processing of HIV gag polyprotein. Antimicrob Agents Chemother (1994) 0.84
SDZ PRI 053, an orally bioavailable human immunodeficiency virus type 1 proteinase inhibitor containing the 2-aminobenzylstatine moiety. Antimicrob Agents Chemother (1995) 0.79
Combination of Antiretroviral Drugs and Radioimmunotherapy Specifically Kills Infected Cells from HIV-Infected Individuals. Front Med (Lausanne) (2016) 0.75
Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A (1988) 10.77
Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science (1985) 10.71
In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp Cell Res (1977) 9.38
Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res (1988) 8.53
Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob Agents Chemother (1993) 4.96
Rational design of peptide-based HIV proteinase inhibitors. Science (1990) 4.57
Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor. Proc Natl Acad Sci U S A (1987) 3.72
A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science (1990) 2.80
HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. Biochem Biophys Res Commun (1988) 2.14
Enzymatic activity of a synthetic 99 residue protein corresponding to the putative HIV-1 protease. Cell (1988) 2.01
Structure-based, C2 symmetric inhibitors of HIV protease. J Med Chem (1990) 1.72
Cooperative dimeric and tetrameric clam haemoglobins are novel assemblages of myoglobin folds. Nature (1985) 1.62
Peptide substrates and inhibitors of the HIV-1 protease. Biochem Biophys Res Commun (1989) 1.52
Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors. Proc Natl Acad Sci U S A (1989) 1.47
Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2. J Biol Chem (1990) 1.29
L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor. J Med Chem (1991) 1.00
Selective phosphinate transition-state analogue inhibitors of the protease of human immunodeficiency virus. Biochem Biophys Res Commun (1990) 0.87
Potent HIV-1 protease inhibitors with antiviral activities in vitro. Biochem Biophys Res Commun (1991) 0.79
Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science (1994) 3.44
Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol (2001) 3.05
Flexibility and function in HIV-1 protease. Nat Struct Biol (1995) 2.49
Pax3 modulates expression of the c-Met receptor during limb muscle development. Proc Natl Acad Sci U S A (1996) 2.35
Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology (1995) 2.29
In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. Proc Natl Acad Sci U S A (1993) 2.16
Molecular cloning of unintegrated and a portion of integrated moloney murine leukemia viral DNA in bacteriophage lambda. J Virol (1980) 2.10
Human chromosome 12 is required for elevated HIV-1 expression in human-hamster hybrid cells. Science (1989) 2.03
Human peripheral blood contains two distinct lineages of dendritic cells. Eur J Immunol (1999) 2.01
Serotype-specific immunoglobulin G antibody responses to pneumococcal polysaccharide vaccine in children with sickle cell anemia: effects of continued penicillin prophylaxis. J Pediatr (1996) 1.84
Multiple integration sites for Moloney murine leukemia virus in productively infected mouse fibroblasts. J Virol (1979) 1.73
Limited sequence diversity of the HIV type 1 protease gene from clinical isolates and in vitro susceptibility to HIV protease inhibitors. AIDS Res Hum Retroviruses (1995) 1.59
Peripheral symmetrical gangrene successfully treated with epoprostenol and tissue plasminogen activator. Lancet (1986) 1.44
Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency. Biochemistry (1998) 1.43
A comparison of the use of polythene sheet and Jelonet as temporary dressings for excised wounds. Br J Plast Surg (1992) 1.39
Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266. AIDS (1996) 1.34
Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med (1986) 1.33
Rhodococcus equi infection in the patient with AIDS: literature review and report of an unusual case. Rev Infect Dis (1991) 1.29
Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV. J Med Chem (1997) 1.27
Plastic surgery audit codes: are the results reproducible? Br J Plast Surg (1991) 1.25
Reducing time limits: a means to increase behavior of retardates. J Appl Behav Anal (1976) 1.24
Determinants of the human immunodeficiency virus type 1 p15NC-RNA interaction that affect enhanced cleavage by the viral protease. J Virol (1997) 1.22
Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas. J Med Chem (1996) 1.20
Virus-secific transcription in 3T3 cells transformed by the ts-a mutant of polyoma virus. J Virol (1977) 1.20
Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors. Biochemistry (1997) 1.18
Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrob Agents Chemother (1999) 1.17
Three-dimensional solution structure of the HIV-1 protease complexed with DMP323, a novel cyclic urea-type inhibitor, determined by nuclear magnetic resonance spectroscopy. Protein Sci (1996) 1.16
Wound infection and septic shock due to Vibrio vulnificus. Am J Trop Med Hyg (1981) 1.13
Plasmid DNA fingerprinting of Acinetobacter calcoaceticus subspecies anitratus from intubated and mechanically ventilated patients. Infect Control Hosp Epidemiol (1990) 1.12
Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues. J Med Chem (1998) 1.09
Endogenous type C retroviral sequences of mice are organized in a small number of virus-like classes and have been acquired recently. J Virol (1981) 1.09
Erythroid colony growth in vitro from human peripheral blood null cells: evidence for regulation by T-lymphocytes and monocytes. Br J Haematol (1981) 1.08
Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. Chem Biol (1996) 1.06
Protein interactions of Src homology 2 (SH2) domain-containing inositol phosphatase (SHIP): association with Shc displaces SHIP from FcgammaRIIb in B cells. J Immunol (1999) 1.05
Scurvy: MRI appearances. Rheumatology (Oxford) (2008) 1.04
Infant mortality and early postpartum discharge. Obstet Gynecol (2000) 1.04
Delayed bactericidal activity of beta-lactam antibiotics against Listeria monocytogenes: antagonism of chloramphenicol and rifampin. Antimicrob Agents Chemother (1983) 1.04
Counteracting HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities. Biochemistry (1998) 1.03
Integrated Moloney murine leukemia virus DNA studied by using complementary DNA which does not recognize endogenous related sequences. J Virol (1980) 1.03
The vascular territory of the acromiothoracic axis. Br J Plast Surg (1984) 1.01
In vitro activities of trimethoprim and sulfamethoxazole against Listeria monocytogenes. Antimicrob Agents Chemother (1982) 1.01
Identification of a clinical isolate of HIV-1 with an isoleucine at position 82 of the protease which retains susceptibility to protease inhibitors. Antiviral Res (1995) 1.01
Endometrial extramedullary haemopoiesis. J Pathol (1995) 1.01
Molecular recognition of cyclic urea HIV-1 protease inhibitors. J Biol Chem (1998) 1.00
Juvenile xanthogranuloma variant: a clinicopathological case report and review of the literature. Br J Plast Surg (1999) 0.98
Telomerase expression in gliomas including the nonastrocytic tumors. Hum Pathol (1998) 0.97
Enhancing legal preparedness for the prevention and control of infectious diseases: experience from severe acute respiratory syndrome in Hong Kong. Public Health (2009) 0.95
Proposed structure of two defective viral DNA oligomers produced in 3T3 cells transformed by the ts-a mutant of polyoma virus. J Virol (1976) 0.94
The mechanism of the anaemia in rheumatoid arthritis: effects of bone marrow adherent cells and of serum on in-vitro erythropoiesis. Br J Haematol (1984) 0.93
Construction of infectious molecular clones of HIV-1 containing defined mutations in the protease gene. Biochem Biophys Res Commun (1994) 0.92
Effectiveness of mattress overlays in reducing interface pressures during recumbency. J Rehabil Res Dev (1985) 0.91
The molecular genetics of central nervous system tumors. Pathology (1998) 0.91
HIV protease inhibitory bis-benzamide cyclic ureas: a quantitative structure-activity relationship analysis. J Med Chem (1996) 0.91
Use of urine for HIV-1 antibody screening. Lancet (1990) 0.90
Analysis of cell cycle regulators: p16INK4A, pRb, and CDK4 in low- and high-grade meningiomas. Hum Pathol (1998) 0.88
4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem Lett (2001) 0.87
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors. J Med Chem (2000) 0.87
Megaloblastic change is a feature of colonies derived from an early erythroid progenitor (BFU-E) stimulated by monocytes in culture. Br J Haematol (1981) 0.86
Multiple malignant melanomas in association with neurofibromatosis type 1. J Plast Reconstr Aesthet Surg (2006) 0.85
Anaemia in juvenile chronic arthritis: serum inhibition of normal erythropoiesis in vitro. Ann Rheum Dis (1987) 0.85
Human chromosome-dependent and -independent pathways for HIV-2 trans-activation. AIDS Res Hum Retroviruses (1991) 0.84
DMP 323, a nonpeptide cyclic urea inhibitor of human immunodeficiency virus (HIV) protease, specifically and persistently blocks intracellular processing of HIV gag polyprotein. Antimicrob Agents Chemother (1994) 0.84
Listeria bacteremia and peritonitis associated with a peritoneovenous shunt: successful treatment with sulfamethoxazole and trimethoprim. J Infect Dis (1984) 0.83
An atraumatic technique for harvesting cancellous bone for secondary alveolar bone grafting in cleft palate. Br J Plast Surg (1985) 0.83
Formes frustes in myeloproliferative disorders. Identification by the growth of an endogenous erythroid clone in vitro in patients with arterial vascular disease. Lancet (1982) 0.83
Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies. J Med Chem (1998) 0.81
The clavicular head of pectoralis major musculocutaneous free flap. Br J Plast Surg (1986) 0.81
Malignant melanoma, evaluation of clinical follow up by questionnaire survey. Br J Plast Surg (1985) 0.81
Antisense epidermal growth factor receptor RNA transfection in human malignant glioma cells leads to inhibition of proliferation and induction of differentiation. Neuropathol Appl Neurobiol (1998) 0.80
Developmental aspects of dendritic cells in vitro and in vivo. Leuk Lymphoma (1998) 0.80
The synthesis of symmetrical and unsymmetrical P1/P1' cyclic ureas as HIV protease inhibitors. Bioorg Med Chem Lett (1998) 0.80
Transcription of isolated mouse liver chromatin. Biochemistry (1976) 0.80
One-stage flap repair with vascularised tendon grafts in a dorsal hand injury using the "Chinese" forearm flap. Br J Plast Surg (1983) 0.79
Effects of CD45 on NF-kappa B. Implications for replication of HIV-1. J Immunol (1994) 0.79
Synthesis and evaluation of efavirenz (Sustiva) analogues as HIV-1 reverse transcriptase inhibitors: replacement of the cyclopropylacetylene side chain. Bioorg Med Chem Lett (2001) 0.79
Fluorescence in situ hybridization analysis of t(3; 12)(q26; p13): a recurring chromosomal abnormality involving the TEL gene (ETV6) in myelodysplastic syndromes. Blood (1996) 0.79
Efavirenz is a potent nonnucleoside reverse transcriptase inhibitor of HIV type 1 replication in microglia in vitro. AIDS Res Hum Retroviruses (2000) 0.79
Unsymmetrical cyclic ureas as HIV-1 protease inhibitors: novel biaryl indazoles as P2/P2' substituents. Bioorg Med Chem Lett (1999) 0.79
Synthesis and evaluation of novel quinolinones as HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem Lett (2001) 0.79